RxDoctor Payments Data

Edward Cullen, MD

Internal Medicine · Oxon Hill, MDNPI 1083775126

Payments from drug & device makers

$263in general payments, 2019–2025

Across 4 payments — averaging $65.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$130
  • Novo Nordisk$106
  • Amgen$16
  • Lilly USA, LLC$12

What the payments were for

  • Food & beverage$25196%
  • Education$124%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boehringer Ingelheim1$130
Novo Nordisk1$106
Amgen1$16
Lilly USA, LLC1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$263 in reported general payments places this provider in the 55th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$250,348
Medicare patients
460
Services billed
7,340

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban89$137,093
XareltoRivaroxaban79$95,180
OzempicSemaglutide52$77,529
JardianceEmpagliflozin57$68,341
RybelsusSemaglutide21$39,924
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$39,767
FarxigaDapagliflozin Propanediol18$29,008
SynjardyEmpagliflozin/Metformin Hcl27$28,489
MyrbetriqMirabegron25$25,602
EntrestoSacubitril/Valsartan22$24,468
Breo ElliptaFluticasone/Vilanterol15$15,540
Valsartan154$6,670
Atorvastatin Calcium402$5,438
SynthroidLevothyroxine Sodium56$5,371
Amlodipine-ValsartanAmlodipine Besylate/Valsartan97$5,351

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$106$117,45373 claims
Boehringer IngelheimJardiance, Synjardy$130$96,83084 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Oxon Hill

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →